Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 24, Pages 6141
Publisher
MDPI AG
Online
2019-12-06
DOI
10.3390/ijms20246141
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role and mechanisms of action of microRNAs in cancer drug resistance
- (2019) Wengong Si et al. Clinical Epigenetics
- De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
- (2019) Vera Magistroni et al. HAEMATOLOGICA
- Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease
- (2018) Susan Branford et al. BLOOD
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
- (2018) Simona Soverini et al. Molecular Cancer
- Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor
- (2018) Yu Zhu et al. ONCOGENE
- Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
- (2018) Monica Bocchia et al. Frontiers in Oncology
- BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
- (2018) Klara Srutova et al. HAEMATOLOGICA
- Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia
- (2018) Ramachandran Krishna Chandran et al. GENE
- Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
- (2017) Ami B. Patel et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Nonhomologous DNA end-joining for repair of DNA double-strand breaks
- (2017) Nicholas R. Pannunzio et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
- (2017) H Zhou et al. LEUKEMIA
- Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia
- (2017) Ayuna Hattori et al. NATURE
- Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia
- (2016) Joanna Antoszewska-Smith et al. ACTA BIOCHIMICA POLONICA
- CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression
- (2016) Anuradha Tarafdar et al. BLOOD
- Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
- (2016) W. Wang et al. BLOOD
- Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
- (2016) Philippe Rousselot et al. CANCER
- ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis
- (2016) Maria Anna Zipeto et al. Cell Stem Cell
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- (2016) M Wagle et al. LEUKEMIA
- Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia
- (2016) G Heller et al. LEUKEMIA
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
- (2016) M. T. Scott et al. Cancer Discovery
- Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
- (2016) Jean Claude Chomel et al. Oncotarget
- shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance
- (2015) J. S. Khorashad et al. BLOOD
- RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study
- (2015) Lijing Shen et al. BMC CANCER
- The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia
- (2015) Fatima Dkhissi et al. EXPERIMENTAL HEMATOLOGY
- An RNA editing fingerprint of cancer stem cell reprogramming
- (2015) Leslie A Crews et al. Journal of Translational Medicine
- Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment
- (2015) Federico Angriman et al. Turkish Journal of Hematology
- Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche
- (2014) D. S. Krause et al. BLOOD
- Single-cell gene expression analysis reveals clonal architecture of blast-phase chronic myeloid leukaemia
- (2014) Arika Nukina et al. BRITISH JOURNAL OF HAEMATOLOGY
- DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia
- (2014) Naomi E. van der Sligte et al. BRITISH JOURNAL OF HAEMATOLOGY
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation
- (2014) Paulina Podszywalow-Bartnicka et al. CELL CYCLE
- Regulation of hematopoietic and leukemic stem cells by the immune system
- (2014) C Riether et al. CELL DEATH AND DIFFERENTIATION
- Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
- (2014) A M Eiring et al. LEUKEMIA
- Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation
- (2014) L Wang et al. LEUKEMIA
- A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
- (2014) L. Ma et al. Science Translational Medicine
- The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors
- (2014) Francesca Pellicano et al. STEM CELLS
- Regulation of mTORC1 by amino acids
- (2014) Liron Bar-Peled et al. TRENDS IN CELL BIOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias
- (2013) C. J. Walker et al. BLOOD
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
- (2012) S. Luatti et al. BLOOD
- Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia
- (2012) L.-J. Zhao et al. BLOOD
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
- (2012) Bin Zhang et al. CANCER CELL
- BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability
- (2012) A Slupianek et al. LEUKEMIA
- Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia
- (2012) Seung-Tae Lee et al. LEUKEMIA RESEARCH
- SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells
- (2012) Z Wang et al. ONCOGENE
- ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia
- (2012) Q. Jiang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia
- (2011) Jungwon Huh et al. ANNALS OF HEMATOLOGY
- Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
- (2011) A. Fabarius et al. BLOOD
- CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia
- (2011) H. Makishima et al. BLOOD
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
- (2011) S. Chu et al. BLOOD
- Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
- (2011) J.-C. Chomel et al. BLOOD
- Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
- (2011) A. Kumari et al. BLOOD
- SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia
- (2011) N. Esposito et al. BLOOD
- Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression
- (2011) C. M. Lucas et al. BLOOD
- Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate
- (2011) Veera S. Nadarajan et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
- (2011) V Grossmann et al. LEUKEMIA
- Expression patterns of microRNAs associated with CML phases and their disease related targets
- (2011) Kateřina Machová Poláková et al. Molecular Cancer
- Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
- (2011) Jaroslav Jelinek et al. PLoS One
- Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia
- (2011) M. Yamamoto-Sugitani et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Deletions of Immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia
- (2010) Elisabeth P Nacheva et al. BMC GENOMICS
- BCR/ABL Stimulates WRN to Promote Survival and Genomic Instability
- (2010) A. Slupianek et al. CANCER RESEARCH
- miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts
- (2010) Anna M. Eiring et al. CELL
- Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy
- (2010) E. Lippert et al. HAEMATOLOGICA
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia
- (2010) Sanne Lugthart et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis
- (2010) S Soverini et al. LEUKEMIA
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Regulation of myeloid leukaemia by the cell-fate determinant Musashi
- (2010) Takahiro Ito et al. NATURE
- Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
- (2010) Michael G Kharas et al. NATURE MEDICINE
- MicroRNAs in Cancer
- (2009) Ramiro Garzon et al. Annual Review of Medicine
- Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia
- (2009) F. Nakahara et al. BLOOD
- SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations
- (2009) D. Nowak et al. BLOOD
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence
- (2009) I Bruns et al. LEUKEMIA
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Up-regulation of WRN and DNA ligase III in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks
- (2008) A. Sallmyr et al. BLOOD
- Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
- (2008) J. Wu et al. BLOOD
- Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
- (2008) I. Iacobucci et al. BLOOD
- RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance
- (2008) C. Roche-Lestienne et al. BLOOD
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- Evi-1 Is a Critical Regulator for Hematopoietic Stem Cells and Transformed Leukemic Cells
- (2008) Susumu Goyama et al. Cell Stem Cell
- Phenotype of blasts in chronic myeloid leukemia in blastic phase—Analysis of bone marrow trephine biopsies and correlation with cytogenetics
- (2008) Alistair G. Reid et al. LEUKEMIA RESEARCH
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
- (2008) Charles G. Mullighan et al. NATURE
- BCR-ABL-transformed GMP as myeloid leukemic stem cells
- (2008) Y. Minami et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis
- (2007) A. M. Eiring et al. BLOOD
- Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis
- (2007) Fabio Stagno et al. LEUKEMIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started